| Patents for A61P 39 - General protective or antinoxious agents (19,019) |
|---|
| 05/31/2001 | WO2000009512A3 Bipyridine manganese complexes |
| 05/31/2001 | US20010002398 (6S)- or 10 (6R,S)- tetrahydrofolic acid is crystallized in a polar medium with pH of 3.5 or greater and have a purity 98% |
| 05/31/2001 | DE19954444A1 Verfahren zum Schutz von Säugetierzellen mittels überexprimierter G-2/M-Zellzykluskoppler A method of protecting mammalian cells by means of overexpressed G-2 / M-Zellzykluskoppler |
| 05/31/2001 | CA2392365A1 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 05/31/2001 | CA2392225A1 Novel il-8 receptor antagonists |
| 05/31/2001 | CA2387591A1 Use of indirubine derivatives for making medicines |
| 05/30/2001 | EP1103272A2 Modulation of TGF-beta by proteolytic enzymes |
| 05/30/2001 | EP1102855A1 Method for producing plants with increased flavonoid and phenolic compound content |
| 05/30/2001 | EP1102762A2 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists |
| 05/30/2001 | EP1102761A2 Cyclopentabenzofuran derivatives and their use |
| 05/30/2001 | EP1102594A1 Use of camptothecin derivatives, with reduced gastrointestinal toxicity |
| 05/30/2001 | EP1102584A2 Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid |
| 05/30/2001 | EP0752992B1 IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN-4-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| 05/30/2001 | CN1297350A Agents for relieving side effects |
| 05/29/2001 | US6239181 Method for preventing and treating peripheral neurophathy by administering selegiline |
| 05/25/2001 | WO2001036454A1 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 05/25/2001 | WO2001036451A1 Vitamin e derivatives |
| 05/25/2001 | WO2001036450A1 S-allylmercaptoglutathione and uses thereof |
| 05/25/2001 | WO2001035999A1 Stable amorphous amifostine composition, and preparation thereof |
| 05/25/2001 | WO2001035961A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/25/2001 | WO2001035943A2 Dextrose and insulin fluid formulation for intravenous infusion |
| 05/25/2001 | WO2000061191A3 Heat stable coated colloidal iron oxides |
| 05/25/2001 | WO2000010588A3 Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs |
| 05/25/2001 | CA2391969A1 S-allylmercaptoglutathione and uses thereof |
| 05/25/2001 | CA2391418A1 Stable amorphous amifostine composition, and preparation thereof |
| 05/23/2001 | EP1101510A1 Condensate of superoxide anion radical abolisher, producing method thereof and superoxide anion radical abolisher powder |
| 05/23/2001 | EP1100507A1 Antioxidant composition and method of treating diseases using same |
| 05/23/2001 | EP1100432A1 Novel uses of ascorbyl-phosphoryl-cholesterol and compositions for practicing same |
| 05/23/2001 | CN1295844A Application of cephalanoplos for antagonizing harmful substance of cigarette |
| 05/22/2001 | US6235772 Lipoic acid analogs |
| 05/17/2001 | WO2001034774A2 Method for protection of mammalian cells by means of over-expressed g-2/m cell cycle coupler |
| 05/17/2001 | WO2001034643A1 24 human secreted proteins |
| 05/17/2001 | WO2001034141A1 Il-8 receptor antagonists |
| 05/17/2001 | WO2001001973A8 Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| 05/17/2001 | WO2001001932A3 Oligosaccharide aldonic acids and their topical use |
| 05/17/2001 | CA2390421A1 24 human secreted proteins |
| 05/16/2001 | EP1098884A1 Il-8 receptor antagonists |
| 05/16/2001 | EP1098659A2 Libraries of polyhydroxamates and their analogs |
| 05/16/2001 | EP1098647A1 Compounds and compositions for treating tissue ischemia |
| 05/16/2001 | EP1098631A1 Pharmaceutical composition in particular for preventing and treating mucositis induced by radiotherapy or chemotherapy |
| 05/16/2001 | CN1295567A Polyethoxylated ascorbic acid derivatives as a novel antioxidant and process for preparing thereof |
| 05/16/2001 | CN1294930A Medicine preparation using tea polyphenol, saponin, Astragalus membranaceus and Lycium chinense as main material |
| 05/16/2001 | CN1294913A Pharmaceutical use of compound |
| 05/15/2001 | US6232497 Method for producing alkali metal and alkaline earth metal pyruvates |
| 05/15/2001 | US6232314 Arylalkylpiperazine compounds as antioxidants |
| 05/10/2001 | WO2001032654A2 Novel heterocyclic compounds and their use as medicines |
| 05/10/2001 | WO2001032648A1 Novel cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof |
| 05/10/2001 | WO2001032624A1 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| 05/10/2001 | WO2001032619A1 Positive modulators of nicotinic receptor agonists |
| 05/10/2001 | WO2001032219A2 Treatment of c. difficile toxin b associated conditions |
| 05/10/2001 | WO2001032156A2 Methods for treating fibroproliferative diseases |
| 05/10/2001 | WO2001032144A1 Dry powder compositions having improved dispersivity |
| 05/10/2001 | WO2000063241A3 Methods and compositions for modulating an immune response |
| 05/10/2001 | WO2000061170A3 Novel medical use of alpha-1-acidic glycoprotein (aag or orosomucoid) |
| 05/10/2001 | US20010001100 For treating narrow-angle glaucoma, Alzheimer's disease, as well as alcohol and nicotine dependence |
| 05/10/2001 | DE19951795A1 Verwendung von Parvoviren zur Verbesserung des Allgemeinzustandes bei Tumorpatienten oder Patienten mit chronischen oder konsumierenden Erkrankungen Use of parvoviruses to improve the general condition in cancer patients or patients with chronic or consumptive diseases |
| 05/10/2001 | CA2388187A1 Treatment of c. difficile toxin b associated conditions |
| 05/10/2001 | CA2387745A1 Positive modulators of nicotinic receptor agonists |
| 05/09/2001 | EP1096932A2 Antihypertensive combination of valsartan and calcium channel blocker |
| 05/09/2001 | CN1294011A 'Gumeihuichun Dan' |
| 05/09/2001 | CN1065433C Oily prepn. and method of prodn. thereof |
| 05/08/2001 | CA2141961C Antioxidant |
| 05/03/2001 | WO2001030784A1 Silicon compounds derived from ascorbic acid |
| 05/03/2001 | WO2001030766A1 Phthalazinone derivatives as pde 4 inhibitors |
| 05/03/2001 | WO2001030759A2 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 05/03/2001 | WO2001030754A2 Micro-cluster liquids and methods of making and using them |
| 05/03/2001 | WO2001030366A2 Use of parvoviruses for improving the general condition of tumour patients or patients having chronic or consumptive diseases |
| 05/03/2001 | WO2001030353A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 05/03/2001 | WO2000065028A3 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| 05/03/2001 | DE19952147A1 Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung New cyclopropanes, pharmaceutical compositions containing them and methods for their preparation |
| 05/03/2001 | CA2389020A1 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 05/03/2001 | CA2388934A1 Micro-cluster liquids and methods of making and using them |
| 05/03/2001 | CA2388611A1 Transdermal drug delivery devices |
| 05/03/2001 | CA2388313A1 Silicon compounds derived from ascorbic acid |
| 05/03/2001 | CA2388121A1 Phthalazinone derivatives as pde 4 inhibitors |
| 05/02/2001 | EP1095656A2 Pharmaceutical preparation comprising Galanthamine as cholinesterase inhibitor |
| 05/02/2001 | EP1095651A2 Multipor food protection |
| 05/02/2001 | EP1095020A1 2-aminopyridine erivatives, their use as medicines and pharmaceutical compositions containing them |
| 05/02/2001 | EP1095007A1 Water-soluble zinc pyruvates or their hydrates, method for the production thereof and their use |
| 05/02/2001 | CN1293067A Use of 4-(4-ethoxybenzyl)-3,6,9-tri(carboxymethyl)-3,6,9-triazohendecanedioic acid calcium composition |
| 05/02/2001 | CN1293036A Use of 4-(4-ethoxygenzyl)-3,6,9-tri(carboxymethyl)-3,6,9-triazohendecanedioic acid calcium composition |
| 05/01/2001 | US6224862 Mixture of prothrombinase and protein; anticoagulant |
| 05/01/2001 | CA2034926C Treatment of poisoning and compositions for use therein |
| 04/26/2001 | WO2001029023A1 Benzopyranyl guanidine derivatives, process for preparation thereof, and pharmaceutical compositions containing them |
| 04/26/2001 | WO2001028366A1 Composition for preventing iodine deficiency |
| 04/26/2001 | WO2001028365A1 Dietary supplement |
| 04/26/2001 | WO2000056889A3 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/26/2001 | WO2000055139A3 Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| 04/25/2001 | EP1093818A1 Powdery preparation for mucosal administration containing polymeric medicine |
| 04/25/2001 | EP1093814A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 04/25/2001 | CN1064845C Plumbism preventing detoxicant |
| 04/24/2001 | US6222051 Alpha-tocopherol 4-aminobenzoic acid ester compounds and method for preparing the same |
| 04/24/2001 | US6222036 Reacting 2-thio-4-dimethyoxymethyl-pyrimidine with acetic acid and catalytic amount of concetrated sulfuric acid to produce 2-thiopyrimidine aldehyde |
| 04/24/2001 | US6221901 Magnesium (-)hydroxycitrate, method of preparation, applications, and compositions in particular pharmaceutical containing same |
| 04/24/2001 | US6221856 Inositol derivatives for inhibiting superoxide anion production |
| 04/24/2001 | US6221355 Anti-pathogen system and methods of use thereof |
| 04/19/2001 | WO2001027268A2 Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| 04/19/2001 | WO2001027140A1 Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
| 04/19/2001 | WO2001027089A1 Pyrimidine derivatives |
| 04/19/2001 | WO2001026676A1 Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1) |